Royal Bank Of Canada Adaptimmune Therapeutics PLC Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.7 - $1.75 $75 - $189	108 Added 18.24%	700 $1,000
Q4 2023 Feb 14, 2024	SELL	$0.43 - $0.79 $7,926 - $14,562	-18,433 Reduced 96.89%	592 $0
Q3 2023 Nov 14, 2023	BUY	$0.73 - $1.04 $13,772 - $19,620	18,866 Added 11865.41%	19,025 $14,000
Q2 2023 Aug 14, 2023	BUY	$0.9 - $1.51 $117 - $196	130 Added 448.28%	159 $0
Q4 2022 Feb 14, 2023	SELL	$1.05 - $2.53 $60 - $146	-58 Reduced 66.67%	29 $0
Q1 2022 May 16, 2022	BUY	$1.73 - $4.06 $5 - $12	3 Added 3.57%	87 $0
Q4 2021 Feb 14, 2022	BUY	$3.5 - $5.68 $294 - $477	84 New	84 $0

152M

78.5K

36.5K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $121M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.